Ionis Pharmaceuticals (IONS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS)

IONS 81.94

-0.3%

Jan 28 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (1927)	4/10/1998 10:37:00 PM
From: sds	Read Replies (1) of 4676

MZ, FDA CAN review as quickly as they wish... I think the FDA will move this along due to that computer system that was highlighted in INC magazine. That's where I see the time advantage coming from. The anti-viral backlog appears low, but I think the FDA will give this more attention as it is the first antisense drug. Bottom line -- the FDA likely won't give this an offial expedited review, and definitely won't give it fast-track, but the combo of computerized submission and low anti-viral backlog makes approval by the end of the year possible. We'll see!! sds

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next